Storia in 5 fonti

Novo Nordisk’s obesity drug Wegovy gets CDSCO approval to treat liver condition

Novo Nordisk's Wegovy receives CDSCO approval as India's first GLP-1 treatment for fatty liver disease, addressing rising health concerns.

Raccontata daopen.onlineeconomictimes.indiatimes.comthehindubusinessline.comhindustantimes.comthehindu.com

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo3 g fa

Novo Nordisk’s obesity drug Wegovy gets CDSCO approval to treat liver condition

Novo Nordisk's Wegovy receives CDSCO approval as India's first GLP-1 treatment for fatty liver disease, addressing rising health concerns.

originale

thehindu.com3 g fa

India approves Novo Nordisk’s weight loss drug Wegovy for fatty liver disease

The Central Drugs Standard Control Organization (CDSCO) has approved Danish major Novo Nordisk’s weight loss drug Wegovy (semaglutide injection 2.4 mg) for a new indication — fatty liver disease.

Leggi questa versione → originale

hindustantimes.com3 g fa

Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease

The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults | India News

Leggi questa versione → originale

economictimes.indiatimes.com3 g fa

Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to…

Leggi questa versione → originale

open.online4 g fa

Semaglutide in pillole, via libera dell’Ue al primo GLP-1 orale per la gestione del peso

Autorizzata la prima versione in compresse di un farmaco della famiglia dei GLP-1 destinato alla gestione del peso

Leggi questa versione → originale

Timeline cronologica

1. giovedì 16 luglio 2026·open.online
   

   Semaglutide in pillole, via libera dell’Ue al primo GLP-1 orale per la gestione del peso

   Autorizzata la prima versione in compresse di un farmaco della famiglia dei GLP-1 destinato alla gestione del peso

2. venerdì 17 luglio 2026·economictimes.indiatimes.com
   

   Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

   India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee…

3. venerdì 17 luglio 2026·thehindubusinessline.com
   

   Novo Nordisk’s obesity drug Wegovy gets CDSCO approval to treat liver condition

   Novo Nordisk's Wegovy receives CDSCO approval as India's first GLP-1 treatment for fatty liver disease, addressing rising health concerns.

4. venerdì 17 luglio 2026·hindustantimes.com
   

   Novo’s weight-loss drug Wegovy gets CDSCO approval for fatty liver disease

   The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults |…

5. venerdì 17 luglio 2026·thehindu.com
   

   India approves Novo Nordisk’s weight loss drug Wegovy for fatty liver disease

   The Central Drugs Standard Control Organization (CDSCO) has approved Danish major Novo Nordisk’s weight loss drug Wegovy (semaglutide injection 2.4 mg) for a new indication —…